Literature DB >> 18496394

Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.

Inder Mainie1, Radu Tutuian, Donald O Castell.   

Abstract

BACKGROUND: The addition of a bedtime H2 receptor antagonist (H2RA) to proton pump inhibitor (PPI) b.i.d. to inhibit nocturnal acid breakthrough (NAB) is controversial. H2RA tolerance has been documented suggesting limitations in its long-term effect. AIM: To compare the intragastric pH and NAB occurring with twice daily PPI with or without the addition of a H2RA.
METHOD: Multichannel intraluminal impedance-pH studies in 100 patients were reviewed. Fifty-eight patients (female 41; mean age, 54 y; range, 17 to 85) were studied on twice daily PPI. Forty-two patients (female 36; mean age, 53 y; range 20 to 85) were studied on a PPI b.i.d.+H2RA for at least 1 month at bedtime. The percentage time of intragastric pH<4 (upright, recumbent, and total) and NAB were compared between the groups.
RESULTS: In the patients with PPI b.i.d. 64% had NAB, compared with only 17% of patients on PPI b.i.d. and H2RA q.h.s. (P<0.001). The percent time intragastric pH<4 for patients on PPI b.i.d. was significantly higher (P<0.01) compared with patients on PPI b.i.d.+H2RA q.h.s. during upright (29.1+/-3.0 vs. 18.3+/-2.9), recumbent (33.5+/-3.4 vs. 12.5+/-3.1), and entire period (31.5+/-2.8 vs. 18.0+/-3.0).
CONCLUSIONS: The addition of a bedtime H2RA reduces the percentage time of the intragastric pH<4 and also NAB. H2RA should be considered as adjunct therapy in whom greater suppression of gastric acid control is considered desirable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18496394     DOI: 10.1097/MCG.0b013e31814a4e5c

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  15 in total

Review 1.  Management of the patient with incomplete response to PPI therapy.

Authors:  Peter J Kahrilas; Guy Boeckxstaens; Andre J P M Smout
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-06       Impact factor: 3.043

Review 2.  Management of refractory typical GERD symptoms.

Authors:  Emidio Scarpellini; Daphne Ang; Ans Pauwels; Adriano De Santis; Tim Vanuytsel; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-14       Impact factor: 46.802

Review 3.  Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Authors:  Yu-Min Kung; Wen-Hung Hsu; Meng-Chieh Wu; Jiunn-Wei Wang; Chung-Jung Liu; Yu-Chung Su; Chao-Hung Kuo; Fu-Chen Kuo; Deng-Chyang Wu; Yao-Kuang Wang
Journal:  Dig Dis Sci       Date:  2017-11-06       Impact factor: 3.199

4.  Respiratory and laryngeal symptoms secondary to gastro-oesophageal reflux.

Authors:  G Rafferty; I Mainie; L P A McGarvey
Journal:  Frontline Gastroenterol       Date:  2011-05-04

5.  EAES recommendations for the management of gastroesophageal reflux disease.

Authors:  Karl Hermann Fuchs; Benjamin Babic; Wolfram Breithaupt; Bernard Dallemagne; Abe Fingerhut; Edgar Furnee; Frank Granderath; Peter Horvath; Peter Kardos; Rudolph Pointner; Edoardo Savarino; Maud Van Herwaarden-Lindeboom; Giovanni Zaninotto
Journal:  Surg Endosc       Date:  2014-05-02       Impact factor: 4.584

6.  Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology.

Authors:  Shobna J Bhatia; Govind K Makharia; Philip Abraham; Naresh Bhat; Ajay Kumar; D Nageshwar Reddy; Uday C Ghoshal; Vineet Ahuja; G Venkat Rao; Krishnadas Devadas; Amit K Dutta; Abhinav Jain; Saurabh Kedia; Rohit Dama; Rakesh Kalapala; Jose Filipe Alvares; Sunil Dadhich; Vinod Kumar Dixit; Mahesh Kumar Goenka; B D Goswami; Sanjeev K Issar; Venkatakrishnan Leelakrishnan; Mohandas K Mallath; Philip Mathew; Praveen Mathew; Subhashchandra Nandwani; Cannanore Ganesh Pai; Lorance Peter; A V Siva Prasad; Devinder Singh; Jaswinder Singh Sodhi; Randhir Sud; Jayanthi Venkataraman; Vandana Midha; Amol Bapaye; Usha Dutta; Ajay K Jain; Rakesh Kochhar; Amarender S Puri; Shivram Prasad Singh; Lalit Shimpi; Ajit Sood; Rajkumar T Wadhwa
Journal:  Indian J Gastroenterol       Date:  2019-12-05

7.  Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy.

Authors:  Joel E Richter
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

Review 8.  Medical Treatment of Gastroesophageal Reflux Disease.

Authors:  Daniel A Kroch; Ryan D Madanick
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

9.  Long-term follow-up after anti-reflux surgery in patients with Barrett's esophagus.

Authors:  Joerg Zehetner; Steven R DeMeester; Shahin Ayazi; Jesse L Costales; Florian Augustin; Arzu Oezcelik; John C Lipham; Helen J Sohn; Jeffrey A Hagen; Tom R DeMeester
Journal:  J Gastrointest Surg       Date:  2010-09-08       Impact factor: 3.452

Review 10.  A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.

Authors:  L Hillman; R Yadlapati; A J Thuluvath; M A Berendsen; J E Pandolfino
Journal:  Dis Esophagus       Date:  2017-09-01       Impact factor: 3.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.